187 related articles for article (PubMed ID: 31176484)
21. Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans.
Cui J; Ren B; Tong Y; Dai H; Zhang L
Virulence; 2015; 6(4):362-71. PubMed ID: 26048362
[TBL] [Abstract][Full Text] [Related]
22. 5-hydroxymethyl-2-furaldehyde from marine bacterium Bacillus subtilis inhibits biofilm and virulence of Candida albicans.
Subramenium GA; Swetha TK; Iyer PM; Balamurugan K; Pandian SK
Microbiol Res; 2018 Mar; 207():19-32. PubMed ID: 29458854
[TBL] [Abstract][Full Text] [Related]
23. Potential Targets for Antifungal Drug Discovery Based on Growth and Virulence in Candida albicans.
Li X; Hou Y; Yue L; Liu S; Du J; Sun S
Antimicrob Agents Chemother; 2015 Oct; 59(10):5885-91. PubMed ID: 26195510
[TBL] [Abstract][Full Text] [Related]
24. Effect of farnesol on Candida dubliniensis biofilm formation and fluconazole resistance.
Jabra-Rizk MA; Shirtliff M; James C; Meiller T
FEMS Yeast Res; 2006 Nov; 6(7):1063-73. PubMed ID: 17042756
[TBL] [Abstract][Full Text] [Related]
25. (1-aryloxy-2-hydroxypropyl)-phenylpiperazine derivatives suppress Candida albicans virulence by interfering with morphological transition.
Zhao S; Huang JJ; Sun X; Huang X; Fu S; Yang L; Liu XW; He F; Deng Y
Microb Biotechnol; 2018 Nov; 11(6):1080-1089. PubMed ID: 30221456
[TBL] [Abstract][Full Text] [Related]
26. Dracorhodin perchlorate inhibits biofilm formation and virulence factors of Candida albicans.
Yang LF; Liu X; Lv LL; Ma ZM; Feng XC; Ma TH
J Mycol Med; 2018 Mar; 28(1):36-44. PubMed ID: 29477784
[TBL] [Abstract][Full Text] [Related]
27. β-citronellol alters cell surface properties of Candida albicans to influence pathogenicity related traits.
Sharma Y; Rastogi SK; Perwez A; Rizvi MA; Manzoor N
Med Mycol; 2020 Jan; 58(1):93-106. PubMed ID: 30843057
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Yeast-to-Hypha Transition and Virulence of
Meng L; Zhao H; Zhao S; Sun X; Zhang M; Deng Y
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670437
[TBL] [Abstract][Full Text] [Related]
29. Enhanced production of farnesol by Candida albicans treated with four azoles.
Hornby JM; Nickerson KW
Antimicrob Agents Chemother; 2004 Jun; 48(6):2305-7. PubMed ID: 15155241
[TBL] [Abstract][Full Text] [Related]
30. Terpenoids of plant origin inhibit morphogenesis, adhesion, and biofilm formation by Candida albicans.
Raut JS; Shinde RB; Chauhan NM; Karuppayil SM
Biofouling; 2013; 29(1):87-96. PubMed ID: 23216018
[TBL] [Abstract][Full Text] [Related]
31. Activity of Allyl Isothiocyanate and Its Synergy with Fluconazole against
Raut JS; Bansode BS; Jadhav AK; Karuppayil SM
J Microbiol Biotechnol; 2017 Apr; 27(4):685-693. PubMed ID: 28138121
[TBL] [Abstract][Full Text] [Related]
32. Targeting Candida albicans filamentation for antifungal drug development.
Vila T; Romo JA; Pierce CG; McHardy SF; Saville SP; Lopez-Ribot JL
Virulence; 2017 Feb; 8(2):150-158. PubMed ID: 27268130
[TBL] [Abstract][Full Text] [Related]
33. Alizarin and Chrysazin Inhibit Biofilm and Hyphal Formation by
Manoharan RK; Lee JH; Kim YG; Lee J
Front Cell Infect Microbiol; 2017; 7():447. PubMed ID: 29085811
[No Abstract] [Full Text] [Related]
34. Antifungal activity of ribavirin used alone or in combination with fluconazole against Candida albicans is mediated by reduced virulence.
Zhang M; Yan H; Lu M; Wang D; Sun S
Int J Antimicrob Agents; 2020 Jan; 55(1):105804. PubMed ID: 31605727
[TBL] [Abstract][Full Text] [Related]
35. Correlation between antifungal resistance and virulence factors in Candida albicans recovered from vaginal specimens.
El-Houssaini HH; Elnabawy OM; Nasser HA; Elkhatib WF
Microb Pathog; 2019 Mar; 128():13-19. PubMed ID: 30562603
[TBL] [Abstract][Full Text] [Related]
36. Relative Abundances of Candida albicans and Candida glabrata in
Olson ML; Jayaraman A; Kao KC
Appl Environ Microbiol; 2018 Apr; 84(8):. PubMed ID: 29427422
[No Abstract] [Full Text] [Related]
37. Efficacy of Compounds Isolated from
Meng L; Sun C; Zhang C; Song S; Sun X; Ju J; Deng Y
Mar Drugs; 2019 Jul; 17(8):. PubMed ID: 31357504
[No Abstract] [Full Text] [Related]
38. Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis.
Navarathna DH; Hornby JM; Hoerrmann N; Parkhurst AM; Duhamel GE; Nickerson KW
J Antimicrob Chemother; 2005 Dec; 56(6):1156-9. PubMed ID: 16239285
[TBL] [Abstract][Full Text] [Related]
39. The antibacterial agent, moxifloxacin inhibits virulence factors of Candida albicans through multitargeting.
Jadhav A; Bansode B; Phule D; Shelar A; Patil R; Gade W; Kharat K; Karuppayil SM
World J Microbiol Biotechnol; 2017 May; 33(5):96. PubMed ID: 28409362
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Biofilm Formation by
Lee JH; Kim YG; Khadke SK; Yamano A; Watanabe A; Lee J
ACS Infect Dis; 2019 Jul; 5(7):1177-1187. PubMed ID: 31055910
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
